152 related articles for article (PubMed ID: 30856230)
1. Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Davis K; Dunseth CD; Mott SL; Cramer-Morales KL; Miller AM; Ear PH; Mezhir JJ; Bellizzi AM; Chan CHF
PLoS One; 2019; 14(3):e0213576. PubMed ID: 30856230
[TBL] [Abstract][Full Text] [Related]
2. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
3. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
[TBL] [Abstract][Full Text] [Related]
4. NAD
Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
[TBL] [Abstract][Full Text] [Related]
5. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma.
Dal Molin M; Brant A; Blackford AL; Griffin JF; Shindo K; Barkley T; Rezaee N; Hruban RH; Wolfgang CL; Goggins M
PLoS One; 2016; 11(10):e0164195. PubMed ID: 27732623
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Sawicka-Gutaj N; Waligórska-Stachura J; Andrusiewicz M; Biczysko M; Sowiński J; Skrobisz J; Ruchała M
Tumour Biol; 2015 Sep; 36(10):7859-63. PubMed ID: 25946974
[TBL] [Abstract][Full Text] [Related]
7. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.
Omori Y; Ono Y; Tanino M; Karasaki H; Yamaguchi H; Furukawa T; Enomoto K; Ueda J; Sumi A; Katayama J; Muraki M; Taniue K; Takahashi K; Ambo Y; Shinohara T; Nishihara H; Sasajima J; Maguchi H; Mizukami Y; Okumura T; Tanaka S
Gastroenterology; 2019 Feb; 156(3):647-661.e2. PubMed ID: 30342036
[TBL] [Abstract][Full Text] [Related]
8. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma.
Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
World J Surg Oncol; 2019 Feb; 17(1):29. PubMed ID: 30736807
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
[TBL] [Abstract][Full Text] [Related]
10. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
11. MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome.
Choi MH; Lee YJ; Yoon SB; Choi JI; Jung SE; Rha SE
Abdom Radiol (NY); 2019 Jan; 44(1):122-130. PubMed ID: 29980829
[TBL] [Abstract][Full Text] [Related]
12. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
13. Tumor recurrence is independent of pancreatic fistula in patients after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Assifi MM; Zhang S; Leiby BE; Pequignot EC; Xia B; Rosato E; Lavu H; Kennedy EP; Yeo CJ; Berger AC
J Am Coll Surg; 2013 Oct; 217(4):621-7. PubMed ID: 23810574
[TBL] [Abstract][Full Text] [Related]
14. High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Peng L; Liang J; Wang H; Song X; Rashid A; Gomez HF; Corley LJ; Abbruzzese JL; Fleming JB; Evans DB; Wang H
Clin Cancer Res; 2010 Jul; 16(14):3734-42. PubMed ID: 20628027
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.
Shackelford RE; Bui MM; Coppola D; Hakam A
Int J Clin Exp Pathol; 2010 Jun; 3(5):522-7. PubMed ID: 20606733
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
17. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
18. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
19. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Zhu S; Bruggeman R; Zaino RJ; Evans DB; Fleming JB; Gomez HF; Zander DS; Wang H
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2598-604. PubMed ID: 20732965
[TBL] [Abstract][Full Text] [Related]
20. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]